Prevention of aspecifically induced bronchoconstriction by PGI2 and 20-methyl-PGI2 in asthmatic patients.
D000293:Adolescent; D000328:Adult; D000403:Airway Resistance; D001249:Asthma / Q000503:physiopathology*; D001986:Bronchial Spasm / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D011464:Epoprostenol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D005082:Physical Exertion; D010919:Placebos; D011453:Prostaglandins / Q000627:therapeutic use*; D013997:Time Factors
D010919:Placebos; D011453:Prostaglandins; D011464:Epoprostenol